Stu Weisbrod

PhD, MBA

Dr. Stuart Weisbrod was the founder and Chief Investment Officer of Iguana Healthcare Partners from January 2010 until closing in June 2018. Previously, Dr. Weisbrod was the founder of the Merlin BioMed Group, a broad-based healthcare investment firm, and served as its Chief Investment Officer from April 1998 until it closed in November 2007. He began his buy-side career at Harpel Advisors in 1994 as a Partner, responsible for the firm’s healthcare and cyclical investment activities. He joined Oracle Partners in January 1995 as a Partner, focusing on the biotechnology and pharmaceutical sectors of healthcare. Dr. Weisbrod served on the Board of Directors of Cambridge Antibody Technology (the original developer of Humira) and on Clinicor (an ophthalmic focused CRO).

Dr. Weisbrod began his investment career as a securities analyst at Prudential-Bache in 1986 and subsequently joined Merrill Lynch as a First Vice President in 1990. From 1987-1993 he consistently ranked in the top three in both the Institutional Investor and Greenwich Associates rankings of biotechnology analysts in the U.S.

Dr. Weisbrod received a Ph.D. in biochemistry from Princeton University in 1980 and an MBA in finance from Columbia University in 1986. From 1980-1984 he held research fellowships at the Medical Research Council Lab in Cambridge, England and at the Cold Spring Harbor Laboratory in New York. For 10 years Dr. Weisbrod served on the Dean’s Council of the Princeton University Graduate School. Dr. Weisbrod served as a Trustee of the Cold Spring Harbor Laboratory from 2017-2024.

​

Dr. Weisbrod has been running his own office since 2018.